Receptor News and Research

RSS

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Researchers at UT Southwestern Medical Center have discovered sets of genes active in cancer cells and normal tissue that predict survival time and potential new treatments for patients with non-small cell lung cancer.

15 Dec 2010

Hemispherx granted extension to modify Ampligen NDA for CFS indication

Hemispherx Biopharma, Inc. announced today that the Food and Drug Administration (FDA) granted a 12 month extension for the Company to modify its NDA in response to a Complete Response Letter (CRL) received November 25, 2009 for the CFS indication.

15 Dec 2010

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Life Science Pharmaceuticals (LSP) announced today a milestone related to monoclonal-antibody (mAb) 806 licensed to Abbott. A Phase 1 trial with ABT-806, a humanized version of mAb 806 that selectively targets the epidermal growth factor receptor (EGFR), has been initiated by Abbott in the U.S. The trial will assess the safety and pharmacokinetics of ABT-806 in patients with advanced solid tumors likely or known to express EGFR.

15 Dec 2010

Neuropeptide S protein boosts memory

UC Irvine researchers have identified a novel mechanism in the brain that boosts memory.

15 Dec 2010

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Researchers at the Andalusian Institute for Molecular Biology and Regenerative Medicine and the University of Granada found that cFLIP -an inhibitor of death ligand-induced apoptosis- is not only essential in breast tumor cells resistance to TRAIL treatments (a death ligand with a potent therapeutic potential against cancer), but this protein is also key to the survival of such cancer cells.

14 Dec 2010

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced that it has initiated a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, a monoclonal antibody designed to enhance the immune system by enabling T cells to more effectively attack cancer cells.

14 Dec 2010

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, announced the results of two separate analyses at national medical conferences.

14 Dec 2010

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

"We provide optimal care to breast cancer patients when we treat the underlying biology of their individual tumors," said Steven Shak, MD, chief medical officer of Genomic Health.

14 Dec 2010

Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence

Orexo AB announces successful completion of the initial pharmacokinetic trial in the OX219 project. In the comparative bioavailability study, the OX219 buprenorphine/naloxone sublingual tablet formulation demonstrated favourable profiles compared to the comparator Suboxone®, which is the market leading product for treatment of opioid dependence.

14 Dec 2010

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

BETHESDA, Md.,GTx, Inc. this weekend presented results of the Capesaris™ (GTx-758) proof of concept pharmacokinetic-pharmacodynamic (PK/PD) clinical trial at the Annual Meeting of the Society of Urologic Oncology.

14 Dec 2010

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

CANCER RESEARCH UK scientists have discovered that a single gene controls the oestrogen-fuelled growth of breast cancer cells, according to research published in Nature Genetics on Sunday.

14 Dec 2010

Bionovo reports positive Menerba clinical program meeting with FDA

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of innovative treatments for women's health and cancer, today announced that it had received the minutes from the U.S. Food and Drug Administration's (FDA) Clinical Guidance meeting that took place on November 8, 2010. In that meeting, the FDA agreed with the Company's proposed overall clinical development plan.

13 Dec 2010

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced today new findings from a clinical study evaluating the company's Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

13 Dec 2010

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces results from two preclinical studies on entinostat, an orally bioavailable, highly selective, class I histone deacetylase (HDAC) inhibitor, in animal models of breast cancer. The data are being presented as oral poster discussions at the San Antonio Breast Cancer Symposium December 8 through December 12 in San Antonio Texas.

13 Dec 2010

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Exemestane, an aromatase inhibitor that blocks production of estrogen, may provide another post-surgery option for postmenopausal women with hormone-receptor positive, early-stage breast cancer.

13 Dec 2010

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

The presence of one to four circulating tumor cells (CTCs) in the blood of early-stage breast cancer patients almost doubled patient's risk of cancer relapse and death, and five or more CTCs increased recurrence by 400 percent and death by 300 percent, according to Phase III results of the SUCCESS trial. These cells were found in patients after surgery but before chemotherapy treatment.

13 Dec 2010

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

A gene target for drug resistance, a triple-drug cocktail for triple negative breast cancer, and patients' risk for carpal tunnel syndrome are among study highlights scheduled to be presented by Johns Hopkins Kimmel Cancer Center scientists during the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12.

13 Dec 2010

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Scientists at the Virginia Bioinformatics Institute at Virginia Tech have discovered some of the key molecular events in the immune system that contribute to inflammatory bowel disease.

13 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

13 Dec 2010

Receptor News and Research

Genes predict survival time, potential new treatments for patients with non-small cell lung cancer

Hemispherx granted extension to modify Ampligen NDA for CFS indication

Abbott initiates ABT-806 Phase 1 trial in EGFR expressing tumors

Neuropeptide S protein boosts memory

cFLIP protein makes breast cancer cells resistant to TRAIL-induced apoptosis

Tolerx commences TRX518 Phase 1 trial in malignant melanoma

Response Genetics presents two gene expression analysis for personalized cancer tharapy selection

Genomic Health announces results of Oncotype DX test in early-stage breast cancer patients

Orexo announces successful completion of OX219 initial pharmacokinetic trial for opioid dependence

GTx announces Capesaris proof of concept clinical trail in men with advanced prostate cancer

FOXA1 gene controls oestrogen-fuelled growth of breast cancer cells

Bionovo reports positive Menerba clinical program meeting with FDA

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

Syndax reports promising results from entinostat preclinical studies in breast cancer

Exemestane may provide post-surgery option for postmenopausal women with hormone-receptor positive breast cancer

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Scientists demonstrate triple-drug cocktail for triple negative breast cancer at AACR symposium

Scientists discover key molecular events in immune system that contribute to inflammatory bowel disease

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

HOXB7 gene raises tamoxifen resistance in women with early-stage breast cancer

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News